New shock-and-kill approach could eradicate barrier to curing HIV
Approach designed to flush out latent viruses has seen tangible success in an animal model, researchers report
By Mary Beth O'Leary Posted on 14 August 2014
Despite tremendous progress in combatting HIV-1 infection with antiretroviral therapy, there is still no cure for the disease because these drugs do not kill a hidden reservoir of infected cells in the body. A study published by Cell Press today in the journal Cell reveals a multipronged strategy for eradicating this latent reservoir and preventing HIV-1 from rebounding after treatment is stopped in mice.
The findings suggest that a "shock-and-kill" approach involving the activation of dormant viruses with drugs called inducers, combined with virus-fighting antibodies, could represent a promising strategy for curing HIV-1 infection in humans.
"This is the first time the shock-and-kill approach designed to flush out latent viruses has seen tangible success in an animal model," said senior study author Dr. Michel Nussenzweig, head of the Laboratory of Molecular Immunology at The Rockefeller University in New York. "The concept will need to be further tested through clinical studies in infected individuals."
Currently, HIV-1 infection can be controlled through a combination of antiretroviral drugs that act at different stages of the virus life cycle. However, these drugs must be taken for life because they do not eliminate inactive viruses within cells. If a patient stops antiretroviral therapy, the previously dormant viruses become activated and detectable in the blood. All previous attempts to alter the HIV-1 reservoir in living animals by combining antiretroviral therapy with other drugs, including inducers that activate genes in latent viruses, have failed.
One potential strategy to overcome this hurdle involves the use of broadly neutralizing antibodies, which can engage the host immune system to kill infected cells. To test this approach and compare it with others, Dr. Nussenzweig and his team injected HIV-1 into mice containing human immune cells and treated them with broadly neutralizing antibodies, inducers, antiretroviral drugs, or combinations of these therapies.
The vast majority of mice treated with antiretroviral therapy alone showed detectable virus levels in the blood after the end of treatment. Similarly, almost all mice treated with broadly neutralizing antibodies combined with a single inducer showed viral rebound after the end of treatment. By contrast, the majority of mice treated with a combination of broadly neutralizing antibodies and three different inducers did not show signs of viral rebound.
"Disrupting the establishment and maintenance of the latent reservoir is a necessary step in curing HIV-1 infection," said lead study author Dr. Ariel Halper-Stromberg of The Rockefeller University. "This study shows that combinations of antibodies and inducers can play a significant role in this process."
Read the article
This article is freely available for two weeks, until August 28, 2014:
Cell, Halper-Stromberg et al.: "Broadly Neutralizing Antibodies and Viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice."
Elsevier Connect Contributor
Mary Beth O'Leary (@MaryBethPress) is Press Officer for Cell Press(@CellPressNews), based in Cambridge, Massachusetts. She began her career at Cell Press as an Senior Editorial Assistant for the journal Cell before transitioning into the marketing/media relations department. As Press Officer, she works closely with the media on communicating the scientific breakthroughs published in Cell Press's 30 journals to the public. A graduate of the College of the Holy Cross in Worcester, Massachusetts, she studied literature and art history.
By Mary Beth O'Leary | Posted on 30 Jul 2014
After HIV is detected in Mississippi baby thought to be cured, researchers look beyond antiretroviral prophylaxisBy Mary Beth O'Leary | Posted on 11 Nov 2013
Delegates from six continents converge on Cell/Lancet conference to discuss breakthroughs and challengesBy John McConnell | Posted on 30 Oct 2013
Cell and The Lancet journals to hold new translational medicine conference in San FranciscoBy Ylann Schemm | Posted on 12 Feb 2013
Photos and videos capture the experience in South Africa, where more than 5.5 million are afflicted